4 research outputs found

    Swift J164449.3+573451 event: generation in the collapsing star cluster?

    Full text link
    We discuss the multiband energy release in a model of a collapsing galactic nucleus, and we try to interpret the unique super-long cosmic gamma-ray event Swift J164449.3+573451 (GRB 110328A by early classification) in this scenario. Neutron stars and stellar-mass black holes can form evolutionary a compact self-gravitating subsystem in the galactic center. Collisions and merges of these stellar remnants during an avalanche contraction and collapse of the cluster core can produce powerful events in different bands due to several mechanisms. Collisions of neutron stars and stellar-mass black holes can generate gamma-ray bursts (GRBs) similar to the ordinary models of short GRB origin. The bright peaks during the first two days may also be a consequence of multiple matter supply (due to matter release in the collisions) and accretion onto the forming supermassive black hole. Numerous smaller peaks and later quasi-steady radiation can arise from gravitational lensing, late accretion of gas onto the supermassive black hole, and from particle acceleration by shock waves. Even if this model will not reproduce exactly all the Swift J164449.3+573451 properties in future observations, such collapses of galactic nuclei can be available for detection in other events.Comment: 7 pages, replaced by the final versio

    Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

    Get PDF
    [No abstract available]Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry

    N-3 fatty acids in patients with multiple cardiovascular risk factors

    No full text
    BACKGROUND: Trials have shown a beneficial effect of n-3 polyunsaturated fatty acids in patients with a previous myocardial infarction or heart failure. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. METHODS: In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 860 general practitioners in Italy. Eligible patients were men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction. Patients were randomly assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 year, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes. RESULTS: Of the 12,513 patients enrolled, 6244 were randomly assigned to n-3 fatty acids and 6269 to placebo. With a median of 5 years of follow-up, the primary end point occurred in 1478 of 12,505 patients included in the analysis (11.8%), of whom 733 of 6239 (11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received placebo (adjusted hazard ratio with n-3 fatty acids, 0.97; 95% confidence interval, 0.88 to 1.08; P=0.58). The same null results were observed for all the secondary end points. CONCLUSIONS: In a large general-practice cohort of patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity. Copyright © 2013 Massachusetts Medical Society

    Cool outflows in galaxies and their implications

    No full text
    corecore